About Anthos Therapeutics
Anthos Therapeutics is a company based in Cambridge (United States) founded in 2019 by Paris Panayiotopoulos and Jonathan Freeman was acquired by Novartis in February 2025. It operates as a HealthTech. Anthos Therapeutics has raised $250 million across 1 funding round from investors including Novartis and Blackstone. The company has 14 employees as of December 31, 2023. Anthos Therapeutics offers products and services including Abelacimab. Anthos Therapeutics operates in a competitive market with competitors including argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others.
- Headquarter Cambridge, United States
- Employees 14 as on 31 Dec, 2023
- Founders Paris Panayiotopoulos, Jonathan Freeman
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anthos Therapeutics
Anthos Therapeutics offers a comprehensive portfolio of products and services, including Abelacimab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Abelacimab is developed as a novel anticoagulant therapy.
Unlock access to complete
Unlock access to complete
Funding Insights of Anthos Therapeutics
Anthos Therapeutics has successfully raised a total of $250M through 1 strategic funding round. The most recent funding activity was a Private Equity Round round of $250 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Private Equity Round — $250.0M
-
First Round
First Round
(28 Feb 2019)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2019 | Amount | Private Equity Round - Anthos Therapeutics | Valuation | Blackstone , Novartis |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Anthos Therapeutics
Anthos Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis and Blackstone. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Founded Year | Domain | Location | |
|
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Anthos Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Anthos Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Anthos Therapeutics Comparisons
Competitors of Anthos Therapeutics
Anthos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, MacroGenics, Alexion, Zai Lab and Kodiak Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs for primary myopathies are developed and targeted.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Anthos Therapeutics
Frequently Asked Questions about Anthos Therapeutics
When was Anthos Therapeutics founded?
Anthos Therapeutics was founded in 2019.
Where is Anthos Therapeutics located?
Anthos Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Anthos Therapeutics?
Bill Meury is the current CEO of Anthos Therapeutics.
Is Anthos Therapeutics a funded company?
Anthos Therapeutics is a funded company, having raised a total of $250M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $250M, raised on Feb 28, 2019.
How many employees does Anthos Therapeutics have?
As of Dec 31, 2023, the latest employee count at Anthos Therapeutics is 14.
What does Anthos Therapeutics do?
Anthos Therapeutics is dedicated to addressing unmet medical needs in the field of anticoagulation. The company is engaged in the development of innovative therapies, particularly targeting Factor XI with their investigational drug Abelacimab. Their work is centered on areas such as atrial fibrillation and cancer-associated thrombosis, aiming to reduce the risk of bleeding compared to traditional treatments. Solutions are being developed to improve patient outcomes in cardiovascular and thrombotic conditions across global healthcare sectors.
Who are the top competitors of Anthos Therapeutics?
Anthos Therapeutics's top competitors include argenx, Zai Lab and Kodiak Sciences.
What products or services does Anthos Therapeutics offer?
Anthos Therapeutics offers Abelacimab.
Who are Anthos Therapeutics's investors?
Anthos Therapeutics has 2 investors. Key investors include Novartis, and Blackstone.